Agamemnon Epenetos qualified in medicine from Glasgow University, Scotland in 1973 and subsequently specialised in Medical Oncology at St. Bartholomew's Hospital, London where he currently holds an Honorary Consultant appointment in Medical Oncology. He has been a practising Oncologist and Cancer Researcher over the last 30 years. He was, until recently, a visiting Professor at Imperial College London. He has published widely on novel cancer therapies and has received much international recognition. Agamemnon has more than 20 years of experience as a biopharmaceutical industry executive. He founded (1988) and served (1990- 2001) as Chairman and R&D Director of Antisoma plc, an oncology-focused biotechnology company listed on the London Stock Exchange. He co-founded (2001) and served as Chairman (2001-2004) of Lipoxen plc, a drug delivery and vaccine company listed on the AIM Market. He also founded (2004) and served as President and CEO (2004-2007) of Somanta Inc. a US cancer therapeutics company listed on the USA OTC/BB. Somanta was acquired in 2007 by Access Pharma , a cancer therapeutics company. He currently serves as Chairman of Trojantec and Alexis Biotech, cancer therapeutic companies and Lifeline, a stem cell therapeutic company.

 Cancer research, cancer stem cells, essentially prohibiting the spread of the cancer,lung cancer.